EGRX / Eagle Pharmaceuticals, Inc. (EGRX) CEO Scott Tarriff on Q1 2022 Results - Earnings Call Transcript

WOODCLIFF LAKE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced more_horizontal

-- CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen's virulence fact more_horizontal

-- Abstract compares relative effects on cognitive function following sedation with Byfavo (remimazolam) for injection versus midazolam -- Abstract co more_horizontal

Eagle Pharmaceuticals (EGRX) came out with quarterly earnings of $1.18 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compar more_horizontal

WOODCLIFF LAKE, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced more_horizontal

Eagle Pharmaceutics Inc. EGRX said Wednesday it has won Food and Drug Administration Qualified Infectious Disease Product (QDIP) and Fast-Track Design more_horizontal

WOODCLIFF LAKE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced more_horizontal

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the n more_horizontal